Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

792 Features
Adult acute leukemia: demand for innovative drugs that prolong survival

11 May 06

A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.
Datamonitor

World Pharmaceutical (China) Summit 2006

10 May 06

This Conference will provide a platform for intellectual discourse in order to answer these questions and to discuss other pressing issues regarding the pharmaceutical industry in China in particular, and the world in general. Opportunities and challenges within the whole value chain, from research and development down to sales and marketing will be discussed and solutions put forward for the benefits of attendees.
IBG Company Limited

New tools for Mental Health Professionals:

27 Apr 06

In many areas there is a long waiting list for CBT delivered by a therapist and these new programmes offer genuine help for patients, which ought to reduce waiting lists and give greater access to services.
Jim Melling

2nd Annual Specialty Pharmaceuticals Global Summit

25 Apr 06

Specialty Pharma transformations and venture investments have continued to grow at an unprecedented pace. The 2006 meeting is an elite opportunity for Big Pharma, Biotech, and Drug Delivery to network with the industry's fastest growing Specialty Pharma companies and discover what makes them so attractive as a partner.
Ed Drilon

Pharma Opportunities in the COPD Market

07 Apr 06

COPD is a disease that will grow in importance in the future and it will have a major impact on society, particular amongst those that smoke. At the moment, although new treatments are being developed for COPD the pharmaceutical market remains undeveloped. There will be a high demand for effective medicines and so COPD should be an area of interest for pharmaceutical companies who specialise in the respiratory therapeutic field.
Dr Faiz Kermani

A Changing Course for Healthcare in Latin America?

07 Apr 06

Healthcare is receiving greater attention in Latin America than ever before and a number of countries in the region are in the midst of major reforms. The government policies that are being developed have important implications for pharmaceutical companies looking to expand in this emerging pharmaceutical region.
Dr Faiz Kermani

Clinical Trials in Cancer

06 Apr 06

SMi’s Clinical Trials in Cancer conference will provide up-to-date information on the current challenges in clinical development, with an insight into European and US regulatory requirements. Attendees will benefit from presentations on key novel therapies currently in development and how they are being integrated into clinical trials. Don't miss this opportunity to meet experts in the field as they discuss how anti-cancer drug development can be optimised and carried forward to achieve the u
Donna-Marie Morgan

What is RSS

05 Apr 06

I recently ran a quick poll on PharmiWeb, to determine what level of awareness there was for RSS (really simple syndication). So...
Mike Wood

Corning Life Sciences Announces New Innovations for Existing Series of Hot Plates, Stirrers, and Stirring Hot Plates

03 Apr 06

Corning Life Sciences today announced the addition of digital displays and enhanced features to its hot plates, stirrers and stirring hot plates. The new digital display features include: a digital temperature display adjustable in 5 degree increments and set temperature indicator; optimum digital stir speed display indicator; and an external temperature controller for precision accuracy “inside the beaker.”
Corning Life Sciences

Corning Life Sciences Announces New Ultra-Low Attachment Surface Products

03 Apr 06

Corning Life Sciences today announced several new products coated with the Ultra-Low Attachment surface including the 25 and 75 cm2 flasks and CELLSTACK® Culture Chambers which are well-suited for many cell culture applications including stem cell, cancer, and immune system research, and enable customers to increase the scale of cell culture, improve yields, and reduce contamination risks
Corning Life Sciences

Search Engine Marketing Health Pharmaceutical Labs clinical

30 Mar 06

Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy.
Elias KAI

Deployable Medicine

29 Mar 06

Deployable medicine involves the complete employment of military health professionals. The nature of the deployment can vary from conventional ‘warfighting’ campaigns to humanitarian relief operations. The methods for employing highly skilled military professionals within the area or operations and the level of care they provide are crucial to the success of the mission
marcus evans

Study supports aggressive use of atorvastatin (Lipitor)

29 Mar 06

The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's atorvastatin/torcetrapib. Studies demonstrating that higher doses of existing products can offer improved efficacy but with no increase in side-effects will also help optimize sales in the antidyslipid
LeadDiscovery

Diagnosing acute congestive heart failure

28 Mar 06

Heart failure affects more than 5 million people in the U.S. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care system cost of $15 billion. Given the paucity of the pipeline for acute congestive heart failure, the best hope of clinical improvement will involve improved utilization of existing therapies. However early intervention requires rapid and accurate diagnosis. Given its diagnostic potential, the measurement of plasma BNP a
LeadDiscovery

PABORD 2006

27 Mar 06

The 2nd international exhibition and conference event focussed exclusively on the theme of outsourcing in the research and development of new medicines. Companies both large and small are adopting this increasingly popular business strategy.
ANDREW CLARK

Cdk5 inhibitors as novel candidate analgesics

22 Mar 06

According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004.  The pain market can be divided into acute pain which is well served by OTC medications, post-operative pain and chronic pain. One of the most challenging areas of analgesia is the treatment of chronic neuropathic pain.  Cancer pain also represents a largely unmet market which along with post-operative analgesia depends to a large extent on opioid-based th
LeadDiscovery

Pharma IQ announces inaugural event in Pharma Sales Force Effectiveness

21 Mar 06

If Sales Force Effectiveness is high on your agenda in the current climate, then don’t miss Pharma IQ’s Next Generation Pharmaceutical Sales Strategies event in June. Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.
Rachel Davis

Big Challenges For Pharma

06 Mar 06

Back in 2000, I was really, really excited. Had I got a date with Kylie Minogue? No. Had West Ham won the Champions League? Not likely. I was excited because I thought I had discovered the best investment sector in the market -- life sciences.
Ed Bowsher

Rituxan approval to mark a new era of B-cell targeted therapies of autoimmune disease?

01 Mar 06

Genentech and Biogen Idec announced yesterday that the FDA has approved Rituxan (Rituximab) for use as a treatment of rheumatoid arthritis. Hopefully this news will mark the start of a new era in the treatment of autoimmune disease.
LeadDiscovery

An Interview with Andrew Copestake Vice President - BD Europe

28 Feb 06

ICON’s core competency is project management, built up over the last fifteen years managing complex projects and underpinned by comprehensive and consistent processes which conform to the ISO9001:2000 quality certification.
Mike Wood

Abbott - Planning to Win

24 Feb 06

A glimpse of the broad-based, versatile business strategy that has enabled Abbott to combine dynamic growth with long-term stability.
Caroline Johnson

Abbott - Pipeline going from strength to strength

24 Feb 06

Abbott recently had the largest gain in reputation of any company in its industry when Fortune magazine ranked it number three in the magazine’s list of the most admired companies in the United States – Fortune’s highest ranking for Abbott since 1989. How was this achieved and what factors led up to it?
Caroline Johnson

Abbott - Global Citizenship

24 Feb 06

In an increasingly complex world, with significant changes taking place on a social, commercial and economic basis almost weekly, corporate social responsibility is a priority for Abbott as it engages its stakeholders, advances its core objectives and exercises its influence – making productive contribution to the societies and communities it operates in.
Caroline Johnson

NK1 receptor antagonists by Roche

23 Feb 06

In their study due to be published in the March edition of Bioorg Med Chem Lett, Hoffmann and colleagues from Roche describe the design of two promising NK1 receptor antagonists, netupitant and befetupitant.
LeadDiscovery

A novel therapeutic candidate for the treatment of lymphomas and other cancers

21 Feb 06

Today's edition of DailyUpdates features work conducted by Imperial College researchers who have identified an aptamer able to reduce the proliferation of lymphoma cells by 40%. This work represents a licensing opportunity. The aptamer is of potential therapeutic use and may be of interest to companies with an interest in biologic approach to oncology. The aptamers also forms the basis of a HTS assay that should help identify small molecule therapeutics for the treatment of hematological cancers
LeadDiscovery

COPD: the silent killer

20 Feb 06

Although COPD is a devastating disease affecting an estimated one in 10 people aged 45 and older, up to 80% of sufferers are unaware they have it. Furthermore, even for patients who do receive treatment, current therapies do not stop the disease's progression. Until better treatments are available, then, efforts must focus on improving smoking cessation therapies and increasing awareness of COPD.
Datamonitor

Gleevec: Improving it utility in exisiting indications; development for extended indications

10 Feb 06

The approval of Novartis’ Glivec in 2001 represents one of the real success stories in the treatment of Chronic myeloid leukaemia. Already generating $2.2 billion in global sales (2005 figures), Glivec is Novartis’ second highest revenue generator and the continued development of this blockbuster seems certain to increase these figures still further. Here we focus on clinical studies aimed at advancing Gleevec as a treatment of small-cell lung cancer
LeadDiscovery

Ghrelin moves back into the limelight of obesity R&D

09 Feb 06

The prevalence of obesity has increased by 61% in the US during the period 1991-2001. According to Datamonitor’s report, Obesity - commercial opportunities and therapeutic pipeline analysis 127m people were classified obese in the seven major markets in 2003. Obesity is an active area of R&D and numerous novel molecular targets are currently being evaluated. One target, ghrelin was the subject of a major target discovery report from LeadDiscovery published in 2003 Ghrelin: Pharmaceutical & Ther
LeadDiscovery

Facts about Dementia

07 Feb 06

The symptoms of Alzheimer’s disease can be treated by a class of drugs known as cholinesterase inhibitors (ChEI’s), which increase the availability of acetylcholine in the brain by inhibiting the enzyme acetylcholinesterase (AChE).
Stephen Cull

Flower power & Oncology

03 Feb 06

The size of the cytotoxic market in the seven major pharmaceutical markets is estimated to be approximately $9.6 billion. Datamonitor expects it to reach a peak of $12.8 billion by 2009. However, mainly due to major patent expiries, it is expected to drop to $11.3 billion by 2014. Topoisomerase inhibitors represent a subgroup of the plant alkaloid class of cytotoxics. DNA topoisomerase II inhibitors are among the most efficacious drugs for the treatment of cancer although they are associated wi
LeadDiscovery

Advertising